NCT02866383View on ClinicalTrials.gov

Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 5, 2022

Study Completion Date

November 30, 2022

Conditions
Metastatic Pancreatic CancerMetastatic Biliary Tract Cancer
Interventions
DRUG

Nivolumab

3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)

DRUG

Ipilimumab

1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)

RADIATION

Radiotherapy

15 Gy x 1 fraction given on day 1

Trial Locations (1)

2730

Herlev & Gentofte Hospital, Herlev

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Herlev Hospital

OTHER